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Prolyl hydroxylase enzymes (PHDs) sense cellular oxygen upstream of hypoxia-inducible 
factor (HIF) signalling leading to HIF degradation in normoxic conditions. Here we 
demonstrate that adipose PHD2 inhibition plays a key role in the suppression of adipocyte 
lipolysis.  Adipose Phd2 gene ablation in mice enhanced adiposity, with a parallel increase in 
adipose vascularization associated with reduced circulating non-esterified fatty acid (NEFA) 
levels and normal glucose homeostasis. Phd2 gene-depleted adipocytes exhibited lower basal 
lipolysis in normoxia and reduced β-adrenergic-stimulated lipolysis in both normoxia and 
hypoxia. A selective PHD inhibitor suppressed lipolysis in murine and human adipocytes in 
vitro and in vivo in mice. PHD2 genetic ablation and pharmacological inhibition attenuated 
protein levels of the key lipolytic effectors hormone-sensitive lipase and adipose triglyceride 
lipase (ATGL), suggesting a link between adipocyte oxygen sensing and fatty acid release. 
PHD2 mRNA levels correlated positively with mRNA levels of AB-hydrolase domain 
containing-5 (ABHD5), an activator of ATGL, and negatively with mRNA levels of lipid 
droplet proteins, perilipin and TIP47 in human subcutaneous adipose tissue.  Therapeutic 
“pseudohypoxia” caused by PHD2 inhibition in adipocytes blunts lipolysis and promotes 
benign adipose tissue expansion and may have therapeutic applications in obesity or 
lipodystrophy. 
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In obesity, the gradual expansion of adipose tissue associates with local hypoxia due to an 
inadequate vascular response (1-2). Hypoxic adipose tissue, as found in diet-induced obesity 
models, or transgenic HIF-1α overexpression in adipose tissue associates with local 
inflammation, fibrosis and metabolic dysfunction (1-6).  In contrast, in models of dietary 
obesity in which adipose tissue hypoxia is attenuated (11β-HSD1 deficient mice, transgenic 
adipose overexpression of VEGF), the structural and metabolic abnormalities are ameliorated 
and benign adipose tissue expansion occurs (7-10). Understanding mechanisms that allow 
benign expansion of adipose depots is of high importance as it may lead to therapeutic 
strategies for minimising the pathogenesis of obesity and/or lipodystrophy syndromes. 
Critical for benign expansion of fat depots is efficient storage and release  of fatty acids in 
adipocytes (11-12) and adequate expandability of the adipose-vascular network (13). Adipose 
tissue expansion is a dynamic process that involves adipocyte hypertrophy in combination 
with vascular re-modelling involving endothelial cells, macrophages and the extracellular 
matrix (13-16). Low oxygen tension (hypoxia) can occur due to an inability of the tissue to 
provide adequate compensatory vascular supply (1-5). In this context, cells respond to 
hypoxia by activation and stabilization of the hypoxia inducible factor alpha isoforms (HIFα) 
(17). Increased HIF-1α activation may contribute to the pathological changes within adipose 
tissue in obesity (1-5) in part through inhibition of peroxisome proliferator-activated receptor 
gamma-2 (PPARg2)-dependent adipogenesis (18). This concept is supported by the 
phenotype of transgenic mice overexpressing Hif1a in adipose tissue which exhibit insulin 
resistance and localised adipose tissue fibrosis (6). In contrast, HIF-2α promotes adipose 
differentiation in vitro and, given that HIF-2α levels are also increased after 4 weeks in high 
fat fed mice (19), may counter-act pathogenic changes associated with HIF-1 at early stages 
of obesity development. The oxygen sensitive signal event that regulates HIF is mediated by 
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hydroxylase enzymes that regulate the protein stability and consequent transcriptional activity 
of HIFα (20). HIF-prolyl hydroxylases (PHDs otherwise known as EGLNs) belong to the 
large family of Fe (II) and 2-oxoglutarate dependent oxygenases (21-24). PHDs hydroxylate 
conserved prolyl residues of the HIF1α and HIF2α subunits, thus promoting their binding to 
the von Hippel Lindau (VHL) tumor suppressor protein, which targets HIFα isoforms for 
proteasomal degradation in normoxia (21-24).  In humans there are three isoforms of PHD 
enzymes (PHD1-3), with PHD2 (EGLN1) the most abundant enzyme, including in mature 
adipocytes (25). PHD2 is the most important for setting basal activity of the HIF system in 
most cells (20).   Despite the growing understanding of the pathological role of HIF1α 
activation in adipose tissue during obesity (1-10, 26-32), direct pharmacological targeting of 
HIF remains challenging. In contrast, therapeutic targeting of PHDs to induce a 
“pseudohypoxic” (activation of HIF-α and target genes in normoxia) state is under active 
clinical development in the context of anemia, and other diseases involving hypoxia (33-34). 
Here we addressed the metabolic consequences and potential therapeutic impact of 
“pseudohypoxia” by genetic and pharmacological inhibition of the principal oxygen sensing 
enzyme PHD2 in adipose tissue.  
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RESEARCH DESIGN AND METHODS 
Animal Studies. The Phd2 conditional allele (35) on a congenic C57BL/6 background, the 
Hif1a conditional allele (36) and the Hif2a conditional allele (37) were crossed with the fatty 
acid binding protein 4 (Fapb4)-Cre allele (38, the Jackson Laboratories) to achieve adipose-
specific conditional knockout mice. Hif1a (stock number 007561) and Hif2a (stock number 
008407) mice were purchased from the Jackson Laboratories. Genotyping and recombination 
efficiency PCRs were performed as previously described (35-39).  In all experiments 
described, control littermates were used for comparisons. For diet induced obesity 
experiments, mice were given the D12331 high fat diet (58% kcal fat; Research Diets Inc) for 
12 weeks. To assess the effect on adipocyte lipolysis of pharmacologically inhibiting PHD, 
we used 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic acid (40-41), a potent 
small molecule inhibitor of the PHD enzymes that has been shown to activate HIFα (40-41). 
For analysis of the effects of this PHD inhibitor (PHI) in vivo, C57BL/6J mice were used. In 
brief, mice were fasted overnight, blood was collected for basal NEFA quantification, mice 
were then divided into 2 groups, those receiving intraperitonal (i.p.) PHI (30mg/kg; a dose 
that was sufficient to robustly induce HIF in liver (41) and a control group receiving vehicle 
(5% DMSO) alone. PHI was administered for an hour prior to CL316,243 (1µg/kg) 
stimulation. Male adult mice were used in all the experiments. Animals were bred under 
standard conditions and fed standard chow (product 801151; Special Diet Services, Essex, 
U.K.) ad libitum unless stated otherwise. Animal studies were performed under licensed 
approval in accordance with the U.K. Home Office Animals (Scientific Procedures) Act, 
1986.  
Systemic Tests and Biochemistry. For glucose tolerance tests mice were fasted 5h before 
administration of glucose (2mg/g BW) orally or by intraperitoneal (i.p) injection. Glucose 
concentration was measured by a blood glucose monitoring system (OneTouchUltra2, 
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Lifescan, Milpitas). For β-3 adrenergic receptor agonist tests, mice were fasted overnight and 
blood samples were collected before and 15, 30 and 60min after i.p. injection of 1µg/kg 
CL316,243 (Sigma-Aldrich, Dorset, U.K.). In the PHD inhibitor experiments, PHI was 
administered i.p. (30mg/kg) and blood collected one hour prior to the i.p. CL316,243  
challenge. Insulin and leptin concentrations were measured using commercial Elisa kits 
(Crystal Chem Inc, Downers Grove). Liver and muscle triglyceride levels were measured 
using a commercial kit (Abcam, Cambridge, U.K.) according to the manufacturer’s 
instructions. 
RT-qPCR. Total RNA was extracted from cells and tissue using TRIZOL (Invitrogen, 
Paisley, U.K.) and treated with DNase I (Invitrogen, Paisley, U.K.). 1 µg total RNA was used 
for first-strand DNA synthesis using Superscript III cDNA Synthesis system (Invitrogen, 
Paisley, U.K.), and qPCR was performed with the Lightcycler 480 (Roche), using mouse-
Taqman assays (Life technologies, Paisley, U.K.) for all genes measured. A standard curve 
was constructed for each gene measured using a serial dilution of cDNA pooled from all 
samples. Results were normalized to the expression of 18S rRNA. 
Immunoblot Assays. Whole cell lysates were prepared  in ice-cold buffer (5 mmol/L 
HEPES, 137 mmol/L NaCl, 1 mmol/L MgCl2, 1 mmol/L CaCl2, 10 mmol/L NaF, 2 mmol/L 
EDTA, 10 mmol/L Na pyrophosphate, 2 mmol/L Na3VO4, 1% Nonidet P-40, and 10% 
glycerol) containing protease inhibitors (Complete Mini; Roche Diagnostics Ltd., West 
Sussex, U.K.) Blots were probed with HIF-1α (Cayman, Ann Arbor, Michigan), HIF2-α 
(Novus Biologicals, Littleton), HIF Prolyl Hydroxylase 2 (Novus Biologicals, Littleton) 
antibodies. Lipolysis activation antibody kit was used to identify HSL, p-HSL660, p-HSL565 
and perilipin (NE Biolabs, Ipswich). The ATGL, AKT and phospho-AKT (Ser473) 
antibodies were from Cell Signaling (Hertfordshire, U.K).  HRP-conjugated anti-rabbit 
(Dako, Cambridgeshire, U.K.) secondary antibody was used. Signal was detected using ECL 
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Plus (GE Healthcare Life Sciences, Buckinghamshire, U.K.). Blots were re-probed with an 
HRP-conjugated anti-actin antibody (Abcam, Cambridge, U.K.). Densitometry was 
performed using the Image J software. 
Histology and Immunohistochemistry. Formalin-fixed, paraffin embedded adipose sections 
(4µm) were used. Images were acquired using a Zeiss microscope (Welwyn Garden City, 
Hertfordshire, U.K.) equipped with a Kodak DCS330 camera (Eastman Kodak, Rochester, 
NY). Adipocyte size was calculated by measuring the diameter of adipocytes from 20 
randomly selected areas per section using a Zeiss KS300 image analyser. Antibodies to CD31 
(Abcam, Cambridge, U.K) for endothelial cells/vessels or F4/80 (Abcam, Cambridge, U.K) 
for macrophages were used. Binding of primary antibody was visualized using DAB, 
Chromogen-A (Dako, Cambridgeshire, U.K). Counter stain was performed by rinsing in 70% 
hematoxilin. Picrosirius red (Sigma Aldrich, Dorset, U.K.) staining of adipose sections was 
used to identify total collagen. Analysis was performed blind to the experimental grouping as 
previously described (7). 
In vitro Adipocyte Lipolysis Experiments. Primary murine or human adipocytes were 
isolated as previously described (7).  For the analysis of lipolysis in aP2-Phd2KO, aP2-
Hif1aKO and aP2-Hif2aKO adipocytes, hypoxic stimulation was performed by replacing the 
media with 1% O2 pre-conditioned media. Cells were left at 1% O2 in a hypoxic chamber 
(1% O2) for 4h, after which media was collected for measurement of NEFA release and cells 
were lysed in RIPA protein lysis buffer for analysis by immunoblotting. Effects of PHI on 
lipolysis were examined in C57BL/6J primary adipocytes. In brief, adipocytes were pre-
treated  with PHI (0.5mM, a sufficient dose to robustly activate HIFα (41) or vehicle (DMSO, 
0.5%) for one hour prior to β-adrenergic stimulation with CL316,243 (100nM) for  three 
hours.  Medium was collected for measuring NEFA concentrations with a NEFA kit (Alpha 
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Labs, Eastleigh, U.K.) and adipocytes were lysed for protein quantification and immunoblot 
analysis. 
Human Adipocyte Lipolysis Studies. Human abdominal subcutaneous adipose tissue was 
obtained, after written consent, from healthy female subjects (age range 30-50years old) with 
mean BMI 25.6 (±1.9 kg/m2) undergoing cosmetic lipectomy procedures. Ethical approval 
for the collection of tissue and subsequent research was granted by the South East Scotland 
Research Ethics Committee 3 (SESREC03), reference number 10/S1103/45.  Adipocytes 
were isolated as above and exposed to PHI as above. In brief, human adipocytes were 
pretreated with PHI or vehicle one hour prior to stimulation with isoproterenol (100nM) for 
additional two hours. Medium was collected for measuring NEFA concentrations and 
adipocytes were lysed for protein quantification and immunoblot analysis. 
Human Adipose Tissue Gene Expression Study. Adipose tissue samples (91 subcutaneous 
and 102 omental abdominal) were obtained from the same location during elective surgical 
procedures [cholecystectomy (n=10), surgery of abdominal hernia (n=14) and gastric by-pass 
surgery (n=78)] from participants with BMI within 20- 68 kg/m2. All subjects were of 
Caucasian origin and reported that their body weight had been stable for at least three months 
before the study. In the obese type 2 diabetic group, 2 subjects were treated with metformin, 
1 with glitazones and 1 with insulin. Liver and renal diseases were specifically excluded by 
biochemical work-up, measuring biomarkers of liver and renal injury. All subjects gave 
written informed consent, approved by the ethical committee (Comitè d’Ètica d’Investigació 
Clínica, CEIC). Adipose tissue samples were immediately frozen in liquid nitrogen and 
stored at -80ºC. RNA was prepared using RNeasy Lipid Tissue Mini Kit (QIAgen,Izasa SA, 
Barcelona, Spain) and integrity checked by Agilent Bioanalyzer (Agilent Technologies, Palo 
Alto, CA) and reverse transcribed to cDNA using High Capacity cDNA Archive Kit (Applied 
Biosystems Inc, Madrid, Spain) according to the manufacturer’s protocol. Gene expression 
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was assessed by real time PCR using a LightCycler® 480 Real-Time PCR System  (Roche 
Diagnostics SL, Barcelona, Spain), using commercially available TaqMan® primer/probe 
sets (Applied Biosystems Inc, Madrid, Spain). A threshold cycle (Ct value) was obtained for 
each amplification curve and a ∆Ct value was first calculated by subtracting the Ct value for 
human Cyclophilin A (PPIA) RNA from the Ct value for each sample. Fold changes 
compared with the endogenous control were then determined by calculating 2-∆Ct. Results are 
expressed as ratio to PPIA gene expression.  
Statistics. Values are reported as mean±SEM. All statistical analysis was performed in 
GraphPad Prism 5 software. Simple comparisons were analysed using Student’s t test. For 
multiple comparisons, differences between genotypes and the effect of treatment(s) were 
analysed by two-way ANOVA with subsequent Tukey’s post hoc test or Mann-Whitney if 
data were not normally distributed. Significance was set at p<0.05. 
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RESULTS 
Adipose Phd2 Deficiency Stabilizes HIFα Levels and Up-regulates HIFα Target Genes.  
We studied inter-cross progeny of the littermate genotype Phd2lox/lox mice (control, designated 
Phd2; described in 35, 39) with the Fabp-4-Cre (aP2-Cre) mice (38) to make an adipose 
tissue selective Phd2 deficiency model designated aP2-Phd2KO. Efficient recombination was 
detected in epididymal (epi), mesenteric (mes) and brown (BAT) adipose tissue and in 
isolated epididymal adipocytes (Supplemental Fig. 1A). Recombination was observed in the 
whole stromal vascular fraction (SVF), but there was no evidence for recombination in 
macrophages (Supplemental Fig. 1A). PHD2 mRNA (Fig. 1A) and protein was efficiently 
knocked down (~70%) in aP2-Phd2KO adipose tissue (Fig. 1B) and in primary adipocytes 
(Fig. 1C) cultured in vitro. No significant Phd2 recombination was found in other tissues 
such us heart, muscle, spleen or liver (Supplemental Fig. 1B). Adipose Phd1 and Phd3 
mRNA levels were unaffected (Supplemental Fig. 1C). Hypoxia markedly up-regulated Phd2 
mRNA levels in vitro (3-fold, p<0.0001) in control adipocytes, but this induction was absent 
in aP2-Phd2KO adipocytes (Fig. 1D).  
Homozygous deletion of Phd2 in adipocytes led to stabilization of HIF-1α and HIF-2α 
protein levels in adipose under normoxic conditions (Fig. 1E-F). HIF target genes encoding 
proteins for nutrient metabolism (Glut1, Glut4, Pdk1, Pdk4) and angiogenesis (Vegfa, 
Angpl4, Tgfb) were higher in white adipose tissue of aP2-Phd2KO compared to control 
littermates (Fig. 2A). Hypoxia led to significantly higher mRNA levels of Glut1 and Vegfa in 
isolated aP2-Phd2KO than control adipocytes (Fig. 2B). In order to evaluate which Hifa 
isoform dominantly regulates target genes in the aP2-Phd2KO model, we measured mRNA 
levels of the same genes in mice with adipose-specific deletion (aP2-Cre-driven deletion) of 
Hif1a (aP2-Hif1aKO) or Hif2a (aP2-Hif2aKO), which blunts the hypoxia-induced 
stabilization of HIF1α in adipocytes (Supplemental Fig. 2A). Deletion of Hif1a in adipose 
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tissue reduced the mRNA levels of genes that control nutrient metabolism (Glut1, Pdk1, 
Pdk4) and the pro-fibrotic response (Tgfb), with pronounced effects in high fat fed animals 
(Fig. 2C). This effect was localised to mature adipocytes (Supplemental Fig. 2 B). In contrast, 
adipose Hif2a deletion reduced the mRNA levels of angiogenic genes (Vegfa, Angpl4) 
(Fig.2D) indicating a predominant role for HIF2a in adipose vascularization.   
Adipose Phd2 Deficiency Increases Adiposity in Parallel with Increased Adipose 
Vascularization.  
Chow diet (low fat)-fed aP2-Phd2KO mice exhibited increased adiposity by 19 weeks of age 
compared to control littermates (Fig. 3A), with ~2-fold higher cumulative weight gain from 
9-30 weeks (Fig. 3B). Adult aP2-Phd2KO mice had more white adipose tissue mass (>50%) 
in all depots, but brown adipose and liver masses were unaltered (Fig. 3C). Body and adipose 
tissue weight differences were not due to increased food intake (Fig. 3D). As expected for 
their higher adiposity, aP2-Phd2KO mice showed a parallel increase in plasma leptin levels 
(Table 1).  
Adipose Phd2 Deficiency Maintains Glucose Tolerance Associated with  Suppressed 
Lipolysis and Reduced Ectopic Lipid Accumulation. 
Despite increased adiposity, aP2-Phd2KO mice exhibited normal glucose tolerance (Fig. 3E) 
and similar fasted and fed plasma insulin levels (Table 1) to their control littermates. aP2-
Phd2KO mice had comparable ad libitum-fed but reduced fasting NEFA levels (after 5 hour 
or overnight fast, Table 1 & Fig. 3F).  Notably, aP2-Phd2KO mice exhibited blunted β-
adrenergic agonist CL316,243 responsiveness in vivo (Fig. 3F), with significantly reduced 
NEFA release. Liver and muscle triglyceride (TAG) levels were lower in aP2-Phd2KO mice 
(Fig. 3G). 
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Greater fat deposition in aP2-Phd2KO mice was associated with larger adipocytes (diameter 
230±12µm, 177±18µm in controls, p=0.034) (Fig. 4A).  However, adipose Phd2 deficiency 
did not affect adipose macrophage density (Fig. 4B) or fibrosis (Fig. 4C, Supplemental Fig. 
3), markers of inflamed and hypoxic adipose tissue respectively. Intriguingly, adipose Phd2 
deficient mice manifested ~2-fold (p=0.001) greater density of immuno-staining for the 
endothelial marker CD31 in adipose tissue indicating an enhanced vascular expansion (Fig. 4 
D-E). 
Because Phd2 deficiency in the model presented here stabilizes both HIFα isoforms, we 
attempted to dissect the role of different HIFα isoforms in adipocyte function in vivo. 
Therefore, aP2-Hif1aKO or aP2-Hif2aKO deficient mice were analysed. Chow-fed aP2-
Hif1aKO or aP2-Hif2aKO were comparable to control littermates (data not shown), therefore 
these mice were analysed after 12 weeks exposure to high fat feeding.  Notably, Hif1a-
deleted mice manifested reduced body weight gain and improved glucose tolerance on high 
fat diet (Supplemental Fig. 4A-C). In contrast, adipose tissue Hif2-deleted mice fed a high fat 
diet gained similar body weight (Supplemental Fig. 4D) but showed worsening of glucose 
tolerance (Supplemental Fig. 4E) and elevated fasting insulin (Supplemental Fig.4F), 
suggesting insulin resistance. There was no difference in plasma fasting NEFA or liver 
triglyceride levels in aP2-Hif2aKO or aP2-Hif2aKO mice compared to their littermate 
controls (Supplemental Table 1). 
Adipose Phd2 Deficiency Leads to Suppression of Lipolytic Signalling.  
To investigate the mechanism by which adipose Phd2 deficiency drives adipocyte 
hypertrophy we assessed lipolytic responses of the adipocytes in vitro under normoxic (21% 
O2) and hypoxic (1% O2) conditions. In normoxia, basal and β-adrenergic–stimulated NEFA 
release into the medium of aP2-Phd2KO adipocytes was significantly lower than control 
(Fig. 5A). The reduced lipolytic response of aP2-Phd2KO adipocytes was also apparent under 
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hypoxic conditions; hypoxia itself attenuated stimulated but not basal lipolysis (Fig. 5A). The 
reduced NEFA release from Phd2-deficient adipocytes was associated with reduced levels of 
the key lipolytic proteins, hormone sensitive lipase (HSL) and perilipin (Fig. 5B- C, 5E). 
Lower HSL mRNA was also observed in aP2-Phd2KO adipose tissue, whereas perilipin 
mRNA levels were unaltered (Fig. 5G). In contrast, the mRNA of the triglyceride synthesis 
gene diacyglycerol acylotransferase-1 (Dgat1) was higher in aP2-Phd2KO adipose tissue.  
Supporting the HIF1α-dependence of this effect, adipocytes from aP2-Hif1aKO and not aP2-
Hif2aKO mice showed a higher basal and β-adrenergic-stimulated NEFA release in hypoxia 
(Fig. 5H) as well as higher total HSL and perilipin protein levels (Fig. 5I-J and quantification 
in Supplemental Fig. 5A-C). Consistent with this, Hif2a-deficient adipocytes showed normal 
NEFA release and HSL levels (Supplemental Fig. 6A-C). Short-term activation of HSL is 
mediated by phosphorylation at Serine 660 (PKA-mediated) and Serine 565 (AMPK-
mediated) (42). Immunoblotting revealed that PHD/HIF-1α affected total HSL protein levels 
but not the phosho-HSL/total HSL protein ratio (Fig. 5 D and F and Supplemental Fig. 5 C). 
In addition, Phd2 deficiency increased expression of the main anti-lipolytic alpha-2 
adrenergic receptor and tended to decrease levels of the lipolytic β3 adrenergic receptor, 
consistent with  greater anti-lipolytic tone in aP2-Phd2KO adipose tissue (Fig. 5G).  
Pharmacological Inhibition of HIF-Prolyl Hydroxylases Suppresses Murine and Human 
Adipocyte Lipolysis.  
We next explored the effect on lipolysis of a small molecule PHD inhibitor (PHI) that 
activates HIFα robustly (40-41). Pharmacological inhibition of PHDs in mouse adipocytes by 
PHI led to a significant stabilization of HIF1α protein levels (10-fold, p=0.026) and to a 
lesser extent HIF2α (Fig. 6A). In both murine (Fig. 6B) and human (Fig. 6C) primary 
adipocytes, PHI elicited a profound suppression of basal and adrenergic agonist-stimulated 
NEFA release in normoxia. As was observed in Phd2-deficient adipocytes (aP2-Phd2KO), 
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total ATGL was not affected but HSL and perilipin protein levels were lower in the PHI-
treated adipocytes (Fig. 6D-E) with no effect on the ratio of phosphorylated HSL to total HSL 
(Fig. 6D) after adrenergic stimulation. PHI-treatment reduced basal ATGL levels (Fig. 6F).   
Administration of PHI to mice in vivo supressed basal plasma NEFA and β-adrenergic-
stimulated NEFA release (Fig. 6G). This effect was consistent with a selective down-
regulation of HSL mRNA levels in adipose tissues from PHI-treated C57BL/6 mice (Fig 6H). 
In human adipocytes in vitro, isoproterenol increased the phosphorylation of AKT (Ser-473) 
in both vehicle and PHI-treated adipocytes (Fig. 6I). However, the ratio of phospho-AKT 
(Ser-473) to total AKT was higher in the PHI-treated human adipocytes (Fig. 6I) suggesting 
selective enhancement of insulin sensitivity with PHD inhibition.   
Adipose PHD2 mRNA Levels Correlate with mRNA Levels of Lipolytic Genes in a 
Depot-specific Manner in Humans. 
We further extended our findings on the role of PHD2 in adipose tissue in a cohort of type 2 
diabetics. Adipose PHD2 (EGLN1) mRNA levels did not correlate with crude measures of 
obesity (BMI; Table 2). However, PHD2 mRNA levels positively correlated with mRNA for 
caveolin (CAV1), a co activator of the lipolytic protein ATGL, ABHD5 and another lipolytic 
cascade-modulating gene, the a-kinase anchoring protein (AKAP). Notably, Type 2 diabetics 
had lower subcutaneous adipose tissue (SAT) PHD2 mRNA levels than non-diabetics (Table 
2).  
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DISCUSSION 
Here we describe a novel biological role for “pseudohypoxia” (see Fig. 7) in the suppression 
of adipocyte lipolysis. Genetic Phd2 deficiency resulted in an increased adipose mass, but 
with normal glucose tolerance and reduced circulating levels of fatty acids. This apparently 
protective adipose expansion was associated with increased vascularity and no increase in 
adipose tissue macrophage burden or fibrosis.  Mechanistic dissection revealed that in 
isolated mouse adipocytes in vitro, basal and β-adrenergic-stimulated release of NEFA was 
reduced by genetic inactivation of Phd2. Importantly, these findings were recapitulated by the 
acute exposure of mouse and human adipocytes to a selective prolyl hydroxylase inhibitor 
that targets PHD2.  
In oxygenated cells, the HIF prolyl hydroxylases promote degradation of HIFα sub-units 
following association of hydroxylated HIF with the VHL ubiquitin E3 ligase. PHD2 is the 
most abundant of these enzymes and is the most important in setting levels of HIF activity in 
normoxic cells (20). Thus, PHD2 inactivation by genetic or pharmacological means is 
predicted to mimic hypoxia, creating a “pseudohypoxic” signal that activates the HIF 
transcriptional cascade in normoxic conditions. Although we cannot be certain that all the 
effects we observed were mediated by this mechanism, several lines of evidence support this. 
First, both HIFα proteins and HIF transcriptional target genes were induced in adipose tissues 
and cells by these interventions. Second, genetic inactivation of Hif1a revealed effects that 
were consistent with induction of HIF being responsible for at least some of the observed 
effects of Phd2 inactivation. In particular, inactivation of Hif1a in adipose tissues resulted in 
reduced body weight gain with high fat feeding, and enhanced lipolytic responses in 
adipocytes.  We therefore propose a model in which Phd2 inactivation leads to co-ordinated 
activation of HIF pathways including marked up-regulation of Vegfα and Angptl4 (most 
likely through HIF2a activation) with concomitant suppression of the key lipolytic enzyme 
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HSL and up-regulation of lipogenesis through Dgat1 to increase fat cell lipid storage. We 
extended our findings to show a positive correlation between PHD2 and ABHD5 in SAT in 
humans. We also found a negative correlation between PHD2 mRNA with mRNA for the 
lipid droplet protein-encoding genes perilipin or TIP47. These data support a role for oxygen 
sensing as an endogenous regulator of adipose tissue lipid mobilisation in humans and 
suggests PHD2 inhibition could promote metabolically protective peripheral fat 
accumulation. In this regard, reduced adipose perilipin protein levels in the ap2-Phd2KO 
mouse model was an unexpected finding, as this might be predicted to promote lipolysis. The 
regulation of the lipolytic machinery is complex and future work will investigate perilipin 
phosphorylation and indeed other lipid droplet protein levels that may reconcile the clearly 
anti-lipolytic effects of PHD inhibition at this functional level.   
A number of observational studies have implicated adipose hypoxia in the pathogenesis of 
insulin resistant-obesity (2-4). Furthermore, several groups have generated transgenic mouse 
models of HIF1α modulation in adipose tissue. Some (5, 29-32), but not all (28, 43, 44) of 
these studies have reported that elevated levels of HIF1α lead to obesity, with fibrotic 
scarring and insulin resistance in the adipose tissue. Consistent with this, genetic inactivation 
or pharmacological inhibition of the HIF system is protective against obesity and its 
associated metabolic abnormalities (32, 33).  Surprisingly, overexpression of HIF1α 
specifically in adipose tissue did not induce canonical HIF-target genes (Vegfa and Glut1) or 
affect the local adipose tissue angiogenic phenotype (5). Instead, HIF1α overexpression 
caused a pro-fibrotic adipose gene expression profile with associated histological 
abnormalities (5). These contrasting findings may reflect context-dependent regulation of 
overlapping target genes by the pleiotropic HIFs. Underlining this complexity, a recent study 
showed no obvious phenotypic changes under normal dietary conditions with an adipose-
selective Phd2 deletion mouse model analogous to ours (43). Indeed, this study reported 
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obesity-resistance in  adipose Phd2-deleted mice (43) in contrast to previous reports showing 
HIF1α activation leads to an obese phenotype (5, 29-32). Moreover, obesity-resistance in the 
adipose-selective Phd2-deleted mice became apparent only after chronic high fat feeding (43) 
The reasons for the discrepancy between these studies could reflect differences in mouse 
strain genetic background, age, dietary intervention and the level of Phd2 deletion achieved. 
Moreover, we did not observe a compensatory Phd3 up-regulation in our ap2-Phd2KO 
model, in contrast to Matsuura et al (43).  Finally, while this manuscript was in revision, 
another study using a hypomorphic Phd2 mutant mouse model of whole-animal PHD2 
deficiency showed an improved metabolic profile with reduced adiposity (44). 
Complementary findings between our study and that of Rahtu-Korpela  et al., are promising 
in terms of the therapeutic potential of PHD inhibitors to improve cholesterol (44) as well as 
reduced plasma NEFA levels (our study) and differences in adiposity phenotypes likely 
reflect our distinct tissue-specific effects versus those of whole-animal Phd2  
hypomorphicity.  In any case, the focus of the work presented here is the effect of PHD/HIF 
signalling on adipocytes in mice and humans under normal dietary conditions and not under 
obesogenic conditions. Indeed, we have shown high fat diets regulate the PHD system (7) 
thus may potentially confound important baseline differences.  
Of note, enlarged adipocytes but normal GTT responses were reported in a distinct genetic 
mouse model of adipose-specific HIF-α activation caused by ablation of the Von Hippel–
Lindau tumour suppressor  (VHL; a factor degrading HIF downstream of PHD action) (45). 
The adipose-specific VHL knockout model exhibited a cardiac hypertrophy phenotype 
resulting from severe adipose inflammation and highlighted the effect of manipulating 
distinct HIF-α isoform levels (45). We show that targeting PHDs, as opposed to VHL, also 
reveals distinct effects and our findings are key in order to fully evaluate which components 
of the HIF signalling pathway are relevant to metabolic pathologies. 
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The “pseudohypoxic” induction of HIF caused by Phd2 deletion may effectively “pre-empt” 
the remodelling effects normally caused by local hypoxia when fat rapidly expands in 
obesity. This may prime adipose tissue to resist the inflammatory and fibrotic responses seen 
with vascular rarefaction in obesity, by activating the pro-angiogenic factors such as Angptl4 
and Vegfa and coordinating more effective vascular remodelling to cope with fat deposition 
(5, 30, 32). Inactivation of Phd2 better mimics the co-ordinated physiological activation of all 
isoforms of HIF system than over-expression of a single isoform. Thus, although in many 
cells PHD2 has greater activity on HIF1α than HIF2α (46), we observed that inactivation of 
Phd2 deficiency in adipose tissue is also associated with stabilization of HIF2α. A large body 
of data now indicates that HIF1α and HIF2α have different, and sometimes opposing, 
biological effects (47). In keeping with this, we observed entirely different responses to the 
inactivation of HIF1α and HIF2α in adipose tissues. Although inactivation of HIF2α did not 
result in altered adipose mass under the experimental conditions used, this does not preclude 
concurrent activation of HIF2α contributing to the phenotype associated with Phd2 
deficiency. Indeed, HIF2α is most likely involved in the pro-angiogenic response of aP2-
Phd2KO mice. It is also possible that quantitative differences in the extent of HIF pathway 
activation underlie the differences in adipose phenotypes, as has been observed in the heart 
(45, 48) and pancreatic β-cell (49, 50) where pronounced induction of HIF is associated with 
organ dysfunction, but modest induction has beneficial effects on metabolic function or 
protection from ischemia. 
Our work reveals a novel role for the oxygen sensor PHD2 in the regulation of adipocyte 
lipolysis. PHD2 inhibition suppresses lipolysis and promotes angiogenic responses through 
distinct HIF isoform activation thereby promoting benign adipose tissue expansion. Notably, 
PHD inhibitors similar to those used in this study are under clinical trials for anemia and 
ischemia (33-34). Although the effects of PHD inhibition in metabolic disease remain to be 
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tested, our data suggest that selective PHD2 inhibition may also be beneficial for 
ameliorating the detrimental metabolic consequences of elevated fatty acid levels found in 
insulin-resistant obesity and lipodystrophic dyslipidaemia.  
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Table 1. Plasma biochemistry in Phd2 and aP2-Phd2KO mice.  
Data are mean ±SEM (n= 6/group). Bold type and asterisks indicate significant differences 
between genotypes. NEFA, non-esterified fatty acids. 
 Phd2 aP2-Phd2KO p value 
Fed  
insulin(ng/ml) 
 
 
3.7±0.8 
 
3.8±0.7 
 
0.87 
Fasted (o/n) 
insulin(ng/ml) 
 
0.08±0.02 0.1±0.01 0.21 
Fasted (5h) insulin 
(ng/ml) 
1.6±0.2 1.6±0.3 0.95 
 
Fed leptin  
(ng/ml) 
 
19.2±4.0 
 
37.2±3.7** 
 
0.009 
 
Fed NEFA  
(mmol/L) 
 
0.8±0.06 
 
0.6±0.09 
 
0.23 
 
Fasted (5h) 
NEFA(mmol/L)  
 
1.1±0.09 
 
0.8±0.04* 
 
0.048 
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Table 2. PHD2 (EGLN1) correlations with genes involved in the lipolytic machinery in 
human subcutaneous (SAT) and visceral (VAT) adipose depots. 
 Non-diabetic 
participants 
Type 2 diabetic 
participants 
P value 
N 73 29  
Age (years) 47.23 ± 12.1 47.55 ± 11.3 0.9 
BMI (kg/m2) 37.7 ± 11.3 41.6 ± 6.8 0.09 
Fasting glucose 
(mg/dL) 
93.01 ± 12.7 163.2 ± 59.8 <0.0001 
EGLN1 (R.U.) in 
SAT  
0.084 ± 0.021 0.070 ± 0.016 0.002 
EGLN1 (R.U.) in 
VAT 
0.082 ± 0.019 0.079 ± 0.020 0.4 
 
All participants 
Non-diabetic 
participants 
Type 2 diabetic 
participants 
SAT r p r p r p 
Age (years) -0.056 0.5 -0.047 0.7 0.046 0.8 
BMI 
(kg/m2) 
0.013 0.9 -0.001 0.9 -0.03 0.9 
Fasting 
glucose 
(mg/dL) 
-0.13 0.2 -0.015 0.9 0.17 0.3 
CAV1 
(R.U.) 
0.47 <0.0001 0.46 <0.0001 0.46 0.03 
ABHD5 
(R.U.) 
0.32 0.01 0.34 0.08 0.11 0.6 
AKAP 
(R.U.) 
0.32 0.01 0.36 0.06 0.55 0.01 
ATGL 
(R.U.) 
0.10 0.4 -0.10 0.5 0.12 0.6 
MGLL 
(R.U.) 
0.14 0.2 0.13 0.4 0.03 0.9 
PRKACA 
(R.U.) 
0.15 0.2 -0.11 0.4 0.68 0.001 
PLIN1 
(R.U.) 
-0.15 0.2 -0.36 0.04 0.16 0.4 
CIDEC 
(R.U.) 
-0.01 0.9 -0.12 0.4 0.12 0.5 
TIP47 
(R.U.) 
-0.27 0.04 -0.25 0.1 -0.14 0.5 
       
       
       
       
       
       
VAT r p r p r p 
Age (years) -0.05 0.6 0.01 0.9 -0.17 0.3 
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BMI 
(kg/m2) 
-0.08 0.4 -0.06 0.5 -0.16 0.3 
Fasting 
glucose 
(mg/dL) 
0.03 0.7 0.11 0.3 0.03 0.8 
CAV1 
(R.U.) 
0.12 0.3 0.13 0.3 0.24 0.3 
ABHD5 
(R.U.) 
0.07 0.6 -0.05 0.8 0.36 0.2 
AKAP 
(R.U.) 
0.07 0.5 0.01 0.9 0.21 0.4 
ATGL 
(R.U.) 
0.07 0.5 0.10 0.5 -0.01 0.9 
MGLL 
(R.U.) 
0.38 0.004 0.42 0.008 0.17 0.5 
PRKACA 
(R.U.) 
-0.06 0.6 -0.06 0.6 -0.12 0.6 
PLIN1 
(R.U.) 
0.17 0.2 0.21 0.2 0.19 0.4 
CIDEC 
(R.U.) 
0.09 0.4 0.045 0.7 0.18 0.4 
TIP47 
(R.U.) 
0.11 0.3 -0.02 0.9 0.38 0.1 
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 FIGURE LEGENDS 
FIG. 1.  
Efficient aP2-Cre-Mediated Knock Down of PHD2 in Adipocytes stabilizes both HIFa 
isoforms. (A) Reduced Phd2 mRNA levels in aP2-Phd2KO (black bars) white adipose tissue 
(WAT) compared to control Phd2 littermates (white bars), n=5. (B) Representative western 
blot showing reduced PHD2 protein levels (upper panel, from left to right lanes 4-6) in aP2-
Phd2KO WAT compared to control littermates (upper panel, lanes 1-3). Mouse embryonic 
fibroblasts lysates from Phd2 wild type (+/+; lane 7) and Phd2 knock out (-/-; lane 8) mice 
were included to identify specificity of the anti-PHD2 antibody.  (C) Reduced PHD2 protein 
levels in aP2-Phd2KO adipocytes, quantification graph of a representative western blot (D) 
Reduced Phd2 mRNA levels in isolated aP2-Phd2KO adipocytes cultured in normoxia 
(21%O
2
) and ablated response to hypoxia (1%O
2
). (E) Representative western blots and (F) 
quantification graph showing stabilization of both HIF1a and HIF2a in adipose tissue in aP2-
Phd2KO adipose.  mRNA was corrected to 18S and protein   to beta ACTIN. Data are 
presented as arbitrary units (AU). * p<0.05, ** p<0.01, *** p<0.001 between genotypes. +++ 
p<0.001 comparison of hypoxia and normoxia within a genotype.  
 
FIG. 2.  
Adipose Phd2 Deficiency Up-Regulates HIF-Target Genes in Normoxia.  
(A) Up-regulation of HIF-a target genes in white adipose tissue of aP2-Phd2KO mice (black 
bars) compared to control Phd2 littermates (white bars) n=7/group. (B) Isolated aP2-Phd2KO 
adipocytes showed higher mRNA levels of Glut1 and Vegfa in both normoxia (21%O2) and 
hypoxia (1%; 4hours), n=3/group. aP2-Hif1aKO (black bars, n=4-11/group) (C) and aP2-
Hif2aKO (black bars, n-=4-6/group) (D) mice with their littermate controls (white bars) were 
fed a control diet or a high fat diet (HF, 58%kcal fat) for 12 weeks.  mRNA levels of HIF-
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target genes in adipose tissue was measured and  corrected to 18S, data are presented as 
arbitrary units (AU).  * p<0.05, ** p<0.01 and *** p<0. 001. 
 
FIG. 3. 
Adipose Phd2 Deficient Mice Exhibit Increased Adiposity, Lower Plasma NEFA Levels 
and Reduced Triglyceride Levels in Liver and Muscle. 
(A) Body weights in chow-fed aP2-Phd2KO (black squares-dashed line) are significantly 
higher after 18 weeks of age compared to Phd2 control mice (open circles-solid line) 
n=7/group. (B) aP2-Phd2KO mice (black bars) gain more weight between 9-30 weeks of age. 
(C) aP2-Phd2KO mice (black bars; n=7) have heavier white fat depots (SC; subcutaneous, 
EPI; epididymal and MES; mesenteric) but similar brown adipose tissue (BAT) and liver 
weights to control Phd2 littermates (white bars; n=5).  (D) Short term food intake was 
recorded between 14-16 weeks of age. There were no apparent differences in food intake 
between genotypes (n=5/group). (E) An intraperitoneal glucose tolerance test (2 mg/g BW 
glucose) in aP2-Phd2KO and control littermate mice (n=6/group). (F) Circulating non-
esterified fatty acids (NEFA) concentrations in aP2-Phd2KO mice before and after 
stimulation with a lipolytic β-3 adrenergic agonist, CL316,243 (1µg/g BW i.p.) (n=5/group). 
(G) Liver and muscle triglyceride (TAG) levels in aP2-Phd2KO (black bars, n=6) and control 
littermate (white bars, n=8) mice.  * p<0.05, ** p<0.01 between genotypes.  
 
FIG. 4. 
Adipose Phd2 Deficiency Increases Adipocyte Size in Parallel with Increased Adipose 
Vasculature. (A) Bigger adipocytes in aP2-Phd2KO mice (black squares, n=6) compared to 
control littermates (open circles, n=5). (B) Similar macrophage numbers (F4/80 positive 
stained) in adipose tissue of aP2-Phd2KO mice. (C) Similar total collagen deposition 
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(Picrosirious Red staining) in aP2-Phd2KO adipose. (D) aP2-Phd2KO adipose tissue has 
more CD31 positive cells and vessels (arrows). (E) Quantification of total vessel number 
corrected for adipocyte number. Magnification x200. * p<0.05, ** p<0.01 between 
genotypes.  
 
 
FIG. 5. 
Phd2 Deficiency Suppresses Adipocyte Lipolysis in vitro. (A) NEFA release in aP2-
Phd2KO isolated adipocytes cultured in normoxia (21%O2) or hypoxia (1%O2) and 
stimulated with CL316,243 (100nM) for 4h show reduced lipolytic responses in both 
normoxia and hypoxia (n=4/group). Induction by CL treatment was significant but has been 
omitted for clarity.  (B) Representative immunoblots of total ATGL, HSL and perilipin and 
phosphorylated HSL at serine 660 and 565 under basal and CL316,243 stimulation in 
normoxia. Labelling on blots WT; Phd2 and KO; aP2Phd2KO. (C) Quantification 
(n=3/group) of immunoblots for total ATGL, HSL and perilipin levels corrected for beta 
ACTIN in normoxia. (D) Level of phosphorylated HSL corrected for total HSL in normoxia. 
Quantification of total HSL and perilipin proteins (E) and phosphorylated  HSLs (F) in 
hypoxia. (G) mRNA levels of key genes involved in the regulation of the adipocyte lipolytic 
response, patatin-like phospholipase domain containing 2 (Atgl) , hormone sensitive lipase 
(Hsl), perilipin 1 (Plin1) and lipogenesis/ fatty acid uptake peroxisome proliferator-activated 
receptor gamma (Pparg2), fatty acid synthase (Fasn), stearoyl-CoA desaturase (Scd1), fatty 
acid translocase (cd36), diacylglycerol acylotransferases (Dgat1 and Dgat2) and adrenergic 
signalling, β3-adrenergic receptor (Adrb3), α2-adrenergic receptor (Adra2) were measured in 
adipose tissue of aP2-Phd2KO mice (black bars, n=6/group) compared to control Phd2 
littermates (white bars, n=6/group). (H) NEFA release in the medium of aP2-Hif1aKO 
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adipocytes (black bars) cultured in normoxia (21%O2) or hypoxia (1%O2) and stimulated 
with CL316,243 show increased lipolytic response in hypoxia (n=4/group). Representative 
immunoblots of HSL and perilipin and phosphorylated HSL at serine 660 and 565 (I) Basal 
and (J) CL316,243 stimulated lipolysis during hypoxia.   * p<0.05, ** p<0.01, ***p<0.001 
comparisons between genotypes within treatment. +p<0.05 indicates significant induction of 
p-HSL660 after CL316,243 stimulation in the control Phd2but not in the aP2-Phd2KO 
adipocytes.  
FIG. 6. 
Pharmacological Inhibition of HIF-Prolyl Hydroxylases Suppresses Murine and Human 
Adipocyte Lipolysis. Primary mouse (n=4/group) and human adipocytes (n=4/group) were 
pre-treated  with a selective PHD inhibitor (PHI, 0.5mM) or vehicle (V;DMSO, 0.5%) for 
1hour prior to a standard β-adrenergic stimulation of lipolysis  by CL316,243 (100nM) or 
isoproterenol (100nM)  for 3hours.  Medium was collected for measuring NEFA 
concentrations and adipocytes were lysed for protein quantification and immunoblot analysis. 
(A) Representative blot shows significant stabilization of HIF1α levels and to a lesser extent 
HIF2α levels by PHI in mouse adipocytes (n=3/group) in normoxia.  (B) Reduced basal and 
CL-stimulated NEFA release in PHI pre-treated mouse adipocytes. (C) Reduced basal and 
isoproterenol stimulated NEFA release in PHI pre-treated human adipocytes. (D) 
Representative mouse adipocyte immunoblots and (E) quantification graph shows unaltered 
ATGL but reduced HSL and perilipin levels after PHI treatment (n=3/group) in stimulated 
lipolysis. Note that ATGL is reduced by PHI in basal lipolysis (F). (G) In vivo administration 
of PHI i.p.(30mg/kg BW) 1h prior to CL i.p. (1µg/g BW) in C57BL/6 mice caused reduction 
of NEFA release compared to vehicle-treated (5% DMSO) mice and a reduced lipolytic 
response after CL316,243 administration (n=6/group). (H) mRNA levels of key lipolytic 
genes  (corrected for 18S levels) in adipose tissue of C57BL/6 administered PHI i.p. 
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(30mg/kg BW, black bars) 1h prior CL316,243 i.p. (1µg/gr BW) or vehicle-treated (5% 
DMSO, white bars) mice administration (n=6/group). Immunoblots (I) and quantification 
graph (J) of phospho-AKT(Ser473), total AKT and ACTIN in human primary adipocytes 
pre-treated with PHI basally and after isoproterenol stimulation (n=3/group).   * p<0.05, ** 
p<0.01, comparisons between PHI and V basally or after β-adrenergic stimulation. +p<0.05 
indicates that in human adipocytes only the vehicle group showed significant NEFA release 
after isoproterenol, the PHI group showed a blunted response.  
FIG.7. 
Schematic summary of the effects of pseudohypoxia in adipose tissue. During excessive 
fat accumulation in obesity (upper panel), the adipose tissue vasculature fails to facilitate this 
expansion and areas of hypoxia are created in adipose tissue (pink shaded areas). This leads 
to activation of HIF1a, recruitment of pro-inflammatory macrophages (light blue shapes), 
collagen deposition and fibrosis (thin brown lines), increased fatty acid release (lipolysis) , 
ectopic fat deposition and insulin resistance;  pathological adipose expansion. In contrast, 
priming adipose tissue to be pseudo-hypoxic, by inhibiting the HIF-prolyl hydroxylases 
(genetic PHD2 deletion or pharmacological PHD inhibition), stabilises HIF1α and HIF2α. 
Adipose tissue expands due to reduced lipolysis and increased lipid storage, leading to 
reduced ectopic lipid deposition. This expansion does not alter the oxygen availability (green 
areas denote normoxia) in the tissue due to enhanced vascularization (red vessel shapes), thus 
leading to safe expansion without insulin resistance.  
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Supplemental Table 1. Plasma NEFA and liver triglyceride levels in aP2-Hif1aKO and 
aP2-Hif2aKO mice under control and high fat diets.   
  
Data are mean±SEM. CD, control chow diet. HFD, high fat diet (58% kcal fat).  NEFA, non-
esterified fatty acids and TAG, triglycerides. 
 
  
Hif1a 
 
CD 
(n=6) 
 
aP2-
Hif1aKO 
CD 
(n=6) 
 
Hif2a 
 
CD 
(n=4) 
 
aP2-
Hif2aKO 
CD 
(n=4) 
 
Hif1a 
 
HFD 
(n=5) 
 
aP2-
Hif1aKO 
HFD 
(n=5) 
 
Hif2a 
 
HFD 
(n=4) 
 
aP2-
Hif2aKO 
HFD 
(n=4) 
 
Plasma 
NEFA 
mmol/L  
(5h fast) 
 
 
1.0±0.07 
 
0.9±0.08 
 
0.8±0.02 
 
1.0±0.05 
 
1.1±0.1 
 
1.1±0.04 
 
0.8±0.05 
 
0.8±0.03 
 
Liver 
TAG 
mmol/L 
corrected 
for protein 
 
0.4±0.07 
 
0.3±0.07 
 
0.2±0.03 
 
0.2±0.05 
 
1.3±0.05 
 
1.2±0.07 
 
1.1±0.16 
 
1.2±0.15 
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 Supplemental FIG. 1 
Phd2 levels were not affected by adipocyte-specific Phd2 deletion in other tissues. (A) A 
schematic view (upper panel) of the genomic PCR used to detect the recombined Phd2 allele 
(450bp)and agarose gel (lower panel) showing recombination in white adipose tissue depots 
(epi; epididymal, mes; mesenteric), brown adipose tissue (BAT) and isolated adipocytes 
(adipo). Note recombination in the stromovascular fraction (SVF) but not in isolated 
peritoneal macrophages (Mφ) in aP2-Phd2KO mice. (B) Recombination PCR gels show that 
there is no recombination (Cre-mediated excision) present in muscle, liver, spleen or heart in 
aP2-Phd2KO tissues.  (C) Adipose Phd2 deficiency (black bars) did not affect adipose Phd1 
or Phd3 mRNA levels.  
Supplemental FIG. 2 
Hif1a deficient adipocytes do not respond to hypoxic stimulus and have reduced HIFα 
target genes.  (A) Adipocytes from aP22-Hif1aKO mice   (black bars, n=3) and Hif1a 
controls (white bars, n=3) were isolated and cultured in 21% O2 or 1% O2 for 6 hours. Cells 
were then lysed and probed with a HIF1α antibody.  Representative blot (upper panel) and 
quantification graph (lower panel) showing significantly ablated HIF1α response in hypoxia 
in aP2-Hif1aKO adipocytes. (B) Glut1 mRNA levels in isolated aP2-Hif1aKO adipocytes 
(black bars) are ~24 fold lower compared to control Hif1a
 
adipocytes (white bars), 
n=3/group. mRNA levels are corrected for 18S and protein for beta ACTIN levels. AU; 
arbitrary units. * p<0.05, ** p<0.01, *** p<0.001 comparisons between genotypes. 
+
p<0.05 
comparison of the effect of hypoxia within genotype. 
Supplemental FIG. 3 
Unaltered pro-fibrotic genes in adipose of aP2-Phd2KO
 
mice. WAT mRNA levels of pro-
fibrotic genes involved in adipose “scarring” such as collagens 1 (Col1), 3 (Col3), 6 (Col6), 
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matrix metalloproteinases 2 and 13 (Mmp2, Mmp13) and the collagen crosslinking protein 
lysyl oxydase (Lox) in aP2-Phd2KO mice (black bars, n=6) were similar to control littermate 
levels (white bars, n=5).  
Supplemental FIG.  4 
Opposing metabolic responses in aP2-Hif1aKO and aP2-Hif2aKO mice during High 
FatFeeding. aP2-Hif1aKO (A-C) and aP2-Hif2aKO (D-F) mice with their littermate controls 
were fed a High fat diet (HF, 58%kcal fat) for 12 weeks.  (A) aP2-Hif1aKO (black squares- 
dashed line, n=6) gained less weight on a HF diet compared to control Hif1a mice (open 
circle-solid line, n=9). (B) aP2-Hif1aKO had similar glucose levels during oral glucose 
tolerance test (OGTT) at 6weeks (open square-dashed line) on HF diet to control  mice and 
retained their glucose response after 12 weeks (black square-bold dashed line) on the diet, in 
contrast  to control mice that showed impairment (open circle versus black circle, n=5/group). 
(C)  Similar insulin levels during the OGTT (n=5/group). (D) aP2-Hif2aKO gained similar 
body weight to control Hif2a mice during HF. (E) aP2-Hif2aKO showed  impaired response 
to OGTT at 6 and 12 weeks on HF diet and (F) aP2-Hif2aKO had higher basal fasting insulin 
during the OGTT compared to control littermates (n=6/group). * p<0.05, 
**p<0.01comparisons between genotypes and +p<0.05 comparisons of time (6-12 weeks) 
within genotype.  
Supplemental FIG. 5 
Adipose Hif1a deficiency induces NEFA release under hypoxic conditions. aP2-Hif1aKO 
adipocytes (black bars) cultured in normoxia (21%O2) or hypoxia (1%O2) and stimulated 
with CL316,243 show increased lipolytic response in hypoxia (n=4/group). Quantification of  
immunoblots of) basal and CL316,243 stimulated HSL, phosphorylated HSL and perilipin 
levels (A-C) (n=3/group) in aP2-Hif1aKO adipocytes in hypoxia. Total HSL and perilipin 
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protein levels are corrected for beta ACTIN (AU), and phosphorylated HSL corrected for 
total HSL (AU). * p<0.05, ***p<0.001 comparisons between genotypes. 
Supplemental FIG.  6 
Adipose Hif2a deficiency does not affect lipolysis. (A) NEFA release in medium of Ap2-
Hif2a (black bars) adipocytes cultured in normoxia (21% O2) or hypoxia (1% O2) and 
stimulated  with CL316,243 show similar lipolytic response to control Hif2a (white bars)
 
adipocytes  (n=4/group). (B) Representative immunoblots of basal total HSL levels and 
quantification graph (n=3/group) in Ap2-Hif2a adipocytes in normoxia and hypoxia. (C) 
Representative immunoblots of CL316,243 stimulated total HSL levels and quantification 
graph (n=3/group) in Ap2-Hif2a adipocytes in nomoxia and hypoxia. Protein levels are 
corrected for beta ACTIN levels. 
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